SCHEMBL7722182

SCHEMBL7722182

CC(C)(C)OC(=O)NCC(=O)Nc1ccc(Cc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.53
NAMPT P43490 2/20 0.50
TLR7 Q9NYK1 1/20 0.49
NPFFR1 Q9GZQ6 1/20 0.49
NPFFR2 Q9Y5X5 1/20 0.49
PPARA Q07869 2/20 0.49
PPARG P37231 2/20 0.49
KMT2A Q03164 1/20 0.49
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
PABPC1 P11940 1/20 0.47
GLS O94925 1/20 0.47
PTPN11 Q06124 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6635582 0.89 NPFFR1 (0.52) NAMPTTLR7NPFFR1NPFFR2KMT2A
SCHEMBL8693590 0.87 CA1 (0.54) CYP17A1NAMPTTLR7KMT2APTPN11
SCHEMBL10249437 0.86 CYP17A1 (0.68) CYP17A1NAMPTPPARAPPARGSLC1A3
SCHEMBL7043590 0.85 LTA4H (0.62) KMT2ANPC1RAB9A
SCHEMBL3218237 0.85 CA1 (0.48) CYP17A1NAMPTTLR7NPFFR1NPFFR2
SCHEMBL23099689 0.84 KMT2A (0.51) NAMPTTLR7NPFFR1NPFFR2PPARA
SCHEMBL15295619 0.83 NAMPT (0.49) CYP17A1NAMPTTLR7PTPN11NPC1
SCHEMBL30483102 0.83 CA1 (0.46) CYP17A1NAMPTTLR7NPFFR1NPFFR2
SCHEMBL17874907 0.83 HPGD (0.50) CYP17A1NAMPTTLR7PTPN11NPC1
SCHEMBL669133 0.82 PTPN11 (0.49) KMT2APTPN11RAB9APOLBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 US disclosed